# TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Source: https://onco.cc/trials/nct05343013/  
OnCo record `nct05343013` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trifluridine/tipiracil in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy is a phase 2, interventional study registered as NCT05343013 by M.D. Anderson Cancer Center, with a registry enrolment figure of 25 participants, started 2022-06-06 and due to reach its primary completion in 2027-05-15. Interventions recorded: TAS-102. Conditions listed: Colorectal Cancer. Primary outcome: To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.. Colorectal eligibility wording from the registry: "Has histological confirmation of colorectal cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05343013
- Phase: 2
- Setting: TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05343013: https://clinicaltrials.gov/study/NCT05343013

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05343013.json